 |
 |
 |
 |
 |
 |
|
||||||||||||||
SELECT PUBLICATIONS
Allred D et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002;30. No abstract available
Fisher B et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169):1993-2000. Abstract
Fisher B et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16(2):441-52. Abstract
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Julian TB et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Presentation. San Antonio Breast Cancer Symposium 2004;Abstract 14.
Mamounas E et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. San Antonio Breast Cancer Symposium 2005;Abstract 29.
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
| Table of Contents | Top of Page |
Editor:
Neil Love, MD
Interviews
Monica Morrow, MD
- Select publications
Kevin R Fox, MD
- Select publications
Thomas B Julian, MD
- Select publications
Robert W Carlson, MD
- Select publications
Richard M Elledge, MD
- Select publications
 |
 |
 |
 |
 |
